New insights into the effect of amorolfine nail lacquer

Mycoses

Volumn 48, Issue 2, 2005, Pages 91-94

  Flagothier, C ^a   Pierard Franchimont C ^a   Pierard G E ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Amorolfine; Antifungal; Fungus; Onychomycosis; Spore

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; DRUG FORMULATION; FUNGUS; FUNGUS GROWTH; FUNGUS SPORE; HUMAN; IN VITRO STUDY; NAIL; ONYCHOMYCOSIS; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PUBLICATION; REINFECTION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; FUNGI; HUMANS; MORPHOLINES; ONYCHOMYCOSIS; SPORES, FUNGAL;

FUNGI;

EID: 15444379429     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2004.01090.x     Document Type: Review

References (32)

1. Arrese JE, Piérard-Franchimont C, Piérard GE. Facing up to the diagnostic uncertainty and management of onychomycoses. Int J Dermatol 1999; 38: S1-6.
2. Arrese JE, Piérard-Franchimont C, Piérard GE. A plea to bridge the gap between antifungals and the management of onychomycosis. Am J Clin Dermatol 2001; 2: 281-4.
3. Polak AM. Preclinical date and mode of action of amorolfine. Clin Exp Dermatol 1992; 1: 8-12.
4. Polak AM, Dixon DM. Antifungal activity of amorolfine in vitro and in vivo. In: Fromtling R (ed.), Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: JR Prous Science Publications, 1987: 555-73.
5. Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817-9.
6. Arrese JE, De Doncker P, Odds F, Piérard GE. Reduction in the growth of non-dermatophyte molds by itracoanzole: evaluation by the corneofungimetry bioassay. Mycoses 1998; 41: 461-5.
7. Takasuka T. Amino acid- or protein-dependent growth of Trichophyton metagrophytes and Trichophyton rubrum. FEMS Immunol Med Mic 2000; 29: 241-5.
8. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in a in vitro model of dermatophyte nail infection. Med Mycol 2004; 42: 159-63.
9. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992; 17: S29-32.
10. Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-3.
11. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 1: 41-43.
12. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychoycosis, once weekly versus twice-weekly. Clin Exp Dermatol 1992; 1: 44-49.
13. Zaug M, Bergstrasser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 18: 61-70.
14. Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4: S23.
15. Maleszka R, Ratajczak V, Turek-Krainska K. The use of amorolfine in the treatment of dermatophyte onychomycosis. Prz Dermatol 2002; 89: 493.
16. Nizet V, Ohtake T, Lauth X et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-7.
17. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002; 110: 823-31.
18. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
19. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
20. Dorschner RA, Lopez-Garcia B, Massie J, Kim C, Gallo RL. Innate immune defense of the nail unit by antimicrobial peptides. J Am Acad Dermatol 2004; 50: 343-8.
21. Schröder JM. Peptides epithéliaux antimicrobiens. Molécules de défenses constitutionnelles locales. Ann Dermatol Venereol 2004; 31: 411-6.
22. Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003; 207: 255-60.
23. Arrese JE, Quatresooz P, Piérard-Franchimont C, Piérard GE. Histomycologie unguéale. Ann Dermatol Venereol 2003; 130: 1254-9.
24. Piérard GE, Arrese JE, Quatresooz P. Histomycologie de la biodiversité des onychomycoses. In: Baran R, Piérard GE (eds), Onychomycoses. Paris: Publ. Abrégés Masson, 2004: 91-104.
25. Rurangirwa A, Piérard-Franchimont C, Piérard GE. Culture of fungi on cyanoacrylate skin surface strippings. A quantitative bioassay for evaluating antifungal drugs. Clin Exp Dermatol 1989; 14: 425-8.
26. Aljabre SH, Richardson MD, Scott EM, Shankland GS. Germination of Trichophyton mentagrophytes on human stratum corneum in vitro. J Med Vet Mycol 1992; 30: 145-52.
27. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32: 429-35.
28. Arrese JE, Fogouang L, Piérard-Franchimont C, Piérard GE. Euclidean and racial computer-assisted corneofungimetry. A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatology 2002; 204: 222-7.
29. Piérard GE, Arrese JE, Piérard-Franchimont C. Itraconazole corneofungimetry bioassay on Malassezia species. Mycoses 2004; 47: 418-21.
30. Piérard GE, Arrese JE, Pierre S et al. Diagnostic microscopique des onychomycoses. Ann Dermatol Venerol 1994; 121: 25-29.
31. Kronauer C, Gfesser M, Ring J, Abeck D. Transonychial water loss in healthy and diseased nails. Acta Dermatol Venereol 2001; 81: 175-7.
32. Piérard GE, Piérard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000; 38: 391-2.